The third generation of quinolones developed in the 1980's was a breakthrough in the practice of antibacterial treatment. Several medicines belonging to this group have been launched on the Hungarian market in the 1990's. The overwhelming success of these medicines is the result of their therapeutic effectiveness offering an alternative to other antibiotics. The present study describes their increasing sales and applications both worldwide and in Hungary. The most important derivatives, such as ciprofloxacin with a worldwide sales of 1 billion USD, ofloxacin norfloxacin and pefloxacin have become available in Hungary by now. In addition to sales in Hungary data of preparations sold in the USA, UK, Germany, France, Italy and Austria are also demonstrated. The place of quinolones among the systematic antibiotics is demonstrated through their sales data. The last part of this paper analyses the average daily costs of quinolone treatments and the average costs of full treatments of the above mentioned six countries, and for Germany and Hungary, compares these data to those of other antibiotics sold for similar therapeutic purpose.
|Number of pages||11|
|Publication status||Published - Jan 1 1993|
ASJC Scopus subject areas